Cystic fibrosis lung – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:18:08 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Cystic fibrosis lung – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Safety and effectiveness study of inhaled ARCT-032 (mRNA therapy) in adults with Cystic Fibrosis https://clinicaltrials.eu/trial/safety-and-effectiveness-study-of-inhaled-arct-032-mrna-therapy-in-adults-with-cystic-fibrosis/ Wed, 29 Apr 2026 15:06:30 +0000 https://clinicaltrials.eu/trial/safety-and-effectiveness-study-of-inhaled-arct-032-mrna-therapy-in-adults-with-cystic-fibrosis/ This clinical trial focuses on Cystic Fibrosis, a genetic condition that affects the lungs and other organs. The study will test a new inhaled treatment called ARCT-032, which contains genetic material (mRNA) designed to help produce a protein that is missing or not working properly in people with Cystic Fibrosis. The purpose is to evaluate if this treatment is safe and well-tolerated by patients with this condition.

The treatment will be delivered using a special device called an eFlow Nebulizer System, which turns the liquid medication into a fine mist that can be inhaled into the lungs. This portable, battery-operated device is quiet and lightweight, making it convenient for patients to use. The study will involve multiple doses of the treatment given over time to determine the most appropriate and safe amount.

During the study, participants will receive increasing doses of ARCT-032 through inhalation. This is particularly important for patients who cannot take other available treatments for Cystic Fibrosis or have not responded well to them. The study will monitor how patients respond to the treatment, including any changes in their breathing function and overall health.

]]> Study on the Safety and Effectiveness of BI 3720931 for Adults with Cystic Fibrosis Who Cannot Use CFTR Modulators https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-bi-3720931-for-adults-with-cystic-fibrosis-who-cannot-use-cftr-modulators/ Wed, 29 Apr 2026 14:28:22 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-bi-3720931-for-adults-with-cystic-fibrosis-who-cannot-use-cftr-modulators/ This clinical trial is focused on studying the effects of a new treatment for cystic fibrosis, a genetic condition that affects the lungs and digestive system. The treatment being tested is called BI 3720931, which is an inhaled gene therapy. Gene therapy is a technique that uses genes to treat or prevent disease. In this study, the therapy is delivered through a nebulizer, a device that turns liquid medicine into a mist to be inhaled into the lungs.

The purpose of the study is to evaluate the safety, tolerability, and effectiveness of a single dose of BI 3720931 in adults with cystic fibrosis who cannot use other treatments known as CFTR modulators. The study will begin with an open-label phase, where all participants will receive the treatment to determine the best dose. This will be followed by a randomized, double-blind phase, where participants will receive either the treatment or a placebo without knowing which one they are getting. This helps to ensure that the results are not biased.

Participants will be monitored for changes in their lung function, specifically looking at a measure called FEV1, which stands for forced expiratory volume in one second. This is a common test to see how well the lungs are working. The study will also track any side effects that occur after receiving the treatment. The trial is expected to continue until 2027, with recruitment starting in late 2024.

]]> Long-Term Safety Study of BI 3720931 for Patients with Cystic Fibrosis from a Previous Trial https://clinicaltrials.eu/trial/long-term-safety-study-of-bi-3720931-for-patients-with-cystic-fibrosis-from-a-previous-trial/ Wed, 29 Apr 2026 14:28:22 +0000 https://clinicaltrials.eu/trial/long-term-safety-study-of-bi-3720931-for-patients-with-cystic-fibrosis-from-a-previous-trial/ This clinical trial focuses on monitoring the long-term health of individuals with cystic fibrosis who previously participated in a study involving a treatment called BI 3720931. Cystic fibrosis is a genetic condition that affects the lungs and digestive system, leading to severe respiratory and digestive problems. The treatment being studied, BI 3720931, is an inhaled gene therapy designed to help manage the symptoms of cystic fibrosis. The purpose of this study is to evaluate the long-term safety and effectiveness of this treatment.

Participants in this study have already received at least one dose of BI 3720931 or a matching placebo in a previous trial. The study will follow these participants over an extended period to observe any potential long-term effects of the treatment. This includes monitoring for any new health issues such as serious infections, neurological disorders, or autoimmune conditions. The study will also track the time it takes for any loss of treatment effectiveness, particularly in lung function, which is measured by a test called forced expiratory volume in 1 second (FEV1).

The study is designed to last up to 15 years, allowing researchers to gather comprehensive data on the long-term impact of BI 3720931. Throughout this period, the occurrence of any serious adverse events will be recorded, providing valuable insights into the safety profile of the treatment. This information will help determine the potential benefits and risks of using BI 3720931 as a long-term treatment option for people with cystic fibrosis.

]]>